Evidence map›Paper›PMID 35811871›Full record

ArticleACS omega2022

Regulating Oncogenic LncRNA DANCR with Targeted ECO/siRNA Nanoparticles for Non-Small Cell Lung Cancer Therapy.

Calin Nicolescu, Amita Vaidya, Andrew Schilb, Zheng-Rong Lu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Calin NicolescuDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States.ORCID https://orcid.org/0000-0003-3942-5586
Amita VaidyaDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States.
Andrew SchilbDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States.
Zheng-Rong LuDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio 44106, United States.ORCID https://orcid.org/0000-0001-8185-9519
Case Western Reserve University · US

Funding

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapyR01CA235152 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI ZHENG-RONG LU, William Schiemann · 2019 to 2026
$3.2M
NCI NIH HHS R01 CA235152
6 · The paper itself

Abstract

Long noncoding RNA (lncRNA) differentiation antagonizing noncoding RNA (DANCR) is a proven oncogenic lncRNA across multiple cancer types. Its effects on cancer cell migration and invasion position it as a potential target for therapy on multiple levels of gene regulation. DANCR is overexpressed in non-small cell lung cancer (NSCLC), the most common lung cancer subtype with poor patient survival. To effectively deliver small interfering RNA (siRNA) against DANCR for NSCLC therapy, we used arginine-glycine-aspartic acid (RGD)-poly(ethylene glycol) (PEG)-(1-aminoethyl)-iminobis[

Identifiers

PMID35811871
PMCPMC9260776
OpenAlexW4283074338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.